European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue SUPPL. 2, 2008, Pages

  Vesikari, Timo ^a   Van Damme, Pierre ^b   Giaquinto, Carlo ^c   Gray, Jim ^d   Mrukowicz, Jacek ^e   Dagan, Ron ^f   Guarino, Alfredo ^g   Szajewska, Hania ^h   Usonis, Vytautas ⁱ  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF PADOVA   (Italy)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Polish Institute for Evidence Based Medicine   (Poland)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Gastroenteritis; Guideline; Recommendation; Rotavirus; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PROBIOTIC AGENT; ROTAVIRUS VACCINE;

BREAST FEEDING; DIARRHEA; DRUG EFFICACY; EMERGENCY WARD; EUROPE; EVIDENCE BASED MEDICINE; FEVER; GASTROENTERITIS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYGIENE; INTUSSUSCEPTION; IRRITABILITY; NUTRITION; ORAL REHYDRATION THERAPY; PASSIVE IMMUNIZATION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; SANITATION; SEROTYPE; SIDE EFFECT; VACCINATION; VIRUS INFECTION; VIRUS SHEDDING; VIRUS TRANSMISSION; VOMITING;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SAFETY; VACCINES, ATTENUATED;

ROTAVIRUS;

EID: 43149086135     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31816f7a10     Document Type: Review

References (82)

1. American Academy of Pediatrics. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007;119:171-82.
2. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-13.
3. European Medicines Agency. RotaTeq Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/rotateq/rotateq.htm. Accessed December 14, 2007.
4. European Medicines Agency. Rotarix Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/rotarix/rotarix.htm. Accessed December 14, 2007.
5. Gray J, Vesikari T, Van Damme P, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008;46 (Suppl 2):S24-31.
6. Mrukowicz J, Szajewska H, Vesikari T. Options for the prevention of rotavirus disease other than vaccination. J Pediatr Gastroenterol Nutr 2008;46 (Suppl 2):S32-7.
7. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-8.
8. Guyatt G, Schunemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:179S-87S.
9. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
10. Newman RD, Grupp-Phelan J, Shay DK, et al. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999;103:E3.
11. Dennehy PH, Cortese MM, Begue RE, et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in US children. Pediatr Infect Dis J 2006;25:1123-31.
12. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:1-45.
13. Zerr DM, Allpress AL, Heath J, et al. Decreasing hospital-associated rotavirus infection: a multidisciplinary hand hygiene campaign in a children's hospital. Pediatr Infect Dis J 2005;24:397-403.
14. Rodriguez WJ, Kim HW, Brandt CD, et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 1987;6:170-6.
15. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8.
16. Simhon A, Mata L, Vives M, et al. Low endemicity and low pathogenicity of rotaviruses among rural children in Costa Rica. J Infect Dis 1985;152:1134-42.
17. Black RE, Lopez de Romana G, Brown KH, et al. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. Am J Epidemiol 1989;129:785-99.
18. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006;25:S7-11.
19. Meszner Z, Banyai K, Pazdiora P, et al. Retrospective analysis of childhood viral gastroenteritis in seven countries in Central and Eastern Europe (CEE). Paper presented at the 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases, Valencia, Spain; May 18-20, 2005.
20. Bernstein DI, Sander DS, Smith VE, et al. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991;164:277-83.
21. Fischer TK, Valentiner-Branth P, Steinsland H, et al. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, West Africa. J Infect Dis 2002;186:593-7.
22. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000;182:1602-9.
23. Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J 2006;25:S42-7.
24. Vesikari T, Isolauri E, D'Hondt E, et al. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-81.
25. World Health Organization. Rotavirus. http://www.who.int/biologicals/ areas/vaccines/rotavirus/en/index.html. Accessed December 14, 2007.
26. Glass RI, Bresee JS, Turcios R, et al. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005;192 (Suppl 1):S160-6.
27. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998;16:381-7.
28. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers, and previously uninfected infants. Vaccine 2004;22:2836-42.
29. Midthun K, Greenberg HB, Hoshino Y, et al. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985;53:949-54.
30. Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996;174 (Suppl 1):S73-80.
31. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996;97:7-13.
32. Joensuu J, Koskenniemi E, Pang XL, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-9.
33. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-7.
34. Glass RI, Bresee JS, Parashar U, et al. Rotavirus vaccines: past, present, and future. Arch Pediatr 2005;12:844-7.
35. Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-20.
36. American Academy of Pediatrics. Prevention of rotavirus disease: guidelines for use of rotavirus vaccines. Pediatrics 1998;102:1483-91.
37. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72.
38. Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception - United States, 1999. MMWR Recomm Rep 2004;53:786-89.
39. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Recomm Rep 1999;48:1007.
40. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998;17:334-40.
41. Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics 2001;107:E97.
42. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Recomm Rep 1999;48:577-81.
43. Simonsen L, Viboud C, Elixhauser A, et al. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005;192 (Suppl 1):S36-43.
44. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002;110:e67.
45. Bines JE. Rotavirus vaccines and intussusception risk. Curr Opin Gastroenterol 2005;21:20-5.
46. Murphy BR, Morens DM, Simonsen L, et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003;187:1301-8.
47. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 2006;24:4821-9.
48. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004;23:937-43.
49. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757-63.
50. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005;192 (Suppl 1):S6-16.
51. Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity, and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005;24:807-16.
52. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
53. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005;24:481-8.
54. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007;119:11-8.
55. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
56. Vesikari T, Van Damme P, Gothefors L, et al. Efficacy of RotaTeq to reduce any severity and severe rotavirus disease in Europe. Paper presented at the 25th International Congress of Pediatrics, Athens, Greece; August 25-30, 2007.
57. Ruuska T, Vesikari T, Delem A, et al. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990;22:269-78.
58. Clark HF, Borian FE, Bell LM, et al. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988;158: 570-87.
59. Dennehy P. An update on the safety profile of pentavalent rotavirus vaccine from the phase III clinical studies. Paper presented at the 12th International Congress on Infectious Diseases, Lisbon, Portugal; June 17-20, 2006.
60. Steele AD, Tumbo J, Armah G, et al. Immunogenicity and reactogenicity of a new live-attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccine in African infants. Paper presented at the 24th International Congress of Pediatrics, Cancun, Mexico; August 15-20, 2004.
61. Steele AD, Tumbo J, Armah G, et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. Paper presented at the 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases, Valencia, Spain; May 18-20, 2005.
62. Matson DO. The pentavalent rotavirus vaccine, RotaTeq. Semin Pediatr Infect Dis 2006;17:195-9.
63. Macias M, López P, Velaquez FR, et al. The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. Paper presented at the 45th Interscience Congress of Antimicrobial Agents and Chemotherapy, Washington, DC; December 16-19, 2005.
64. Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity, and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J 2003;22:914-20.
65. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004;144:184-90.
66. Vesikari T. Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. Paper presented at the 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases, Valencia, Spain; May 18-20, 2005.
67. Vesikari T, Matson D, Van Damme P, et al. Incidence of intussusception with the pentavalent (human-bovine) reassortant rotavirus vaccine (PRV) is similar to placebo. Paper presented at the 23rd Annual Meeting of the European Society for Paediatric Infectious Disease, Valencia, Spain; May 18-20, 2005.
68. US Food and Drug Administration. Public Health Notification: Information on RotaTeq and Intussusception. http://www.fda.gov/cber/safety/phnrota021307. htm. Accessed December 14, 2007.
69. Haber P. Update of RotaTeq Vaccine Reports to VAERS, 03/01/06-09/25/07. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct07/31RV. pdf. Accessed December 14, 2007.
70. Heaton P. Results of the phase III studies evaluating the safety and efficacy of the investigational pentavalent human-bovine reassortant rotavirus vaccine, RotaTeq. Paper presented at the meeting of the Advisory Committee of Immunization Practices. Atlanta, GA; June 29-30, 2005.
71. Vesikari T, Prymula R, Schuster V, et al. Rotarix (RIX4414), and oral human rotavirus vaccine, is highly immunogenic when co-administered with diptheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe. Paper presented at the 24th Annual Meeting of the European Society for Paediatric Infectious Diseases, Basel, Switzerland; May 3-5, 2006.
72. Schuster V, Otto W, Cohen R, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcos pneumoniae conjugate vaccine (Prevenar) in healthy infants from France and Germany. Paper presented at the 24th Annual Meeting of the European Society of Paediatric Infectious Diseases, Basel, Switzerland; May 3-5, 2006.
73. Tejedor JC, Diez-Delegado J, Aristegui J, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitidis serogroup C vaccine (Meningitec) in healthy infants from Spain. Paper presented at the 24th Annual Meeting of the European Society of Paediatric Infectious Diseases, Basel, Switzerland; May 3-5, 2006.
74. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007;26:221-7.
75. Ciarlet M, Sani-Grosso R, Yuan G, et al. Safety and immunogenicity of concomitant use of the pentavalent rotavirus vaccine (RotaTeq) and oral poliovirus vaccine (OPV). Paper presented at the 25th Annual Meeting of the European Society for Paediatric Infectious Diseases, Porto, Portugal; May 2-4, 2007.
76. Fontana M, Zuin G, Mammino A, et al. Rotavirus infection and diarrhea in healthy and HIV-infected children: a cohort study. J Pediatr Gastroenterol Nutr 1996;23:492-6.
77. Guarino A, Albano F, Canani RB, et al. HIV, fatal rotavirus infection, and treatment options. Lancet 2002;359:74.
78. Goveia MG, Rodriguez ZM, Dallas MJ, et al., and the REST Study TeamSafety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007;26:1099-104.
79. Nelson EA, Tam JS, Glass RI, et al. Incidence of rotavirus diarrhea and intussusception in Hong Kong using standardized hospital discharge data. Pediatr Infect Dis J 2002;21:701-3.
80. Chang EJ, Zangwill KM, Lee H, et al. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J 2002;21:97-102.
81. Hutchison IF, Olayiwola B, Young DG. Intussusception in infancy and childhood. Br J Surg 1980;67:209-12.
82. Tai JH, Curns AT, Parashar UD, et al. Rotavirus vaccination and intussusception: can we decrease temporally associated background cases of intussusception by restricting the vaccination schedule? Pediatrics 2006;118:e258-64.